{
  "title": "Phentermine/topiramate",
  "content-preview": "Phentermine/topiramate, sold under the brand names Qsymia or QSIVA, is a combination drug of phentermine and topiramate used to treat obesity. It is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped. The we",
  "url": "https://en.wikipedia.org/wiki/Phentermine/topiramate",
  "pageid": 25720535,
  "title-terms": {
    "phenterminetopiramate": 1
  },
  "content-terms": {
    "phenterminetopiramate": 13,
    "sold": 1,
    "brand": 1,
    "names": 1,
    "qsymia": 2,
    "qsiva": 1,
    "combination": 2,
    "drug": 4,
    "phentermine": 5,
    "topiramate": 8,
    "used": 2,
    "treat": 1,
    "obesity": 1,
    "together": 1,
    "dietary": 1,
    "changes": 1,
    "exercise": 2,
    "less": 1,
    "3": 2,
    "weight": 6,
    "loss": 3,
    "seen": 1,
    "months": 1,
    "recommended": 3,
    "medication": 1,
    "stopped": 1,
    "modest": 1,
    "effects": 7,
    "heart": 5,
    "related": 1,
    "health": 1,
    "problems": 1,
    "death": 1,
    "unclear": 1,
    "common": 2,
    "side": 4,
    "include": 2,
    "tingling": 2,
    "dizziness": 2,
    "trouble": 1,
    "sleeping": 1,
    "constipation": 2,
    "serious": 1,
    "may": 1,
    "suicide": 1,
    "abuse": 1,
    "use": 3,
    "pregnancy": 6,
    "stimulant": 1,
    "appetite": 1,
    "suppressant": 1,
    "anticonvulsant": 1,
    "exact": 1,
    "mechanism": 1,
    "action": 1,
    "drugs": 2,
    "unknown": 1,
    "approved": 3,
    "medical": 2,
    "united": 1,
    "states": 1,
    "2012": 4,
    "october": 4,
    "approval": 2,
    "denied": 2,
    "europe": 1,
    "due": 4,
    "concerns": 4,
    "regarding": 2,
    "safety": 2,
    "2024": 1,
    "poland": 1,
    "scandinavia": 1,
    "uses": 1,
    "clinical": 3,
    "trials": 3,
    "people": 3,
    "treated": 2,
    "highest": 1,
    "dose": 3,
    "er": 10,
    "program": 2,
    "diet": 1,
    "lost": 1,
    "10": 1,
    "11": 1,
    "body": 2,
    "compared": 3,
    "1": 2,
    "2": 1,
    "received": 1,
    "placebo": 3,
    "addition": 1,
    "62": 1,
    "70": 1,
    "subjects": 1,
    "receiving": 2,
    "top": 1,
    "achieved": 1,
    "\u22655": 2,
    "reduction": 1,
    "week": 1,
    "56": 1,
    "ittlocf": 1,
    "17": 1,
    "21": 1,
    "cochrane": 1,
    "review": 2,
    "longterm": 2,
    "weightreducing": 1,
    "hypertension": 1,
    "found": 1,
    "reduced": 2,
    "orlistat": 1,
    "naltrexonebupropion": 1,
    "also": 1,
    "blood": 1,
    "pressure": 1,
    "adverse": 3,
    "events": 2,
    "occurred": 1,
    "rate": 5,
    "\u226515": 1,
    "times": 1,
    "included": 1,
    "paraesthesia": 1,
    "fingerstoes": 1,
    "altered": 1,
    "taste": 1,
    "insomnia": 1,
    "dry": 1,
    "mouth": 1,
    "us": 2,
    "label": 1,
    "contains": 1,
    "warnings": 2,
    "increased": 3,
    "suicidal": 1,
    "behavior": 1,
    "ideation": 1,
    "glaucoma": 2,
    "mood": 1,
    "sleep": 1,
    "disorders": 1,
    "creatinine": 1,
    "elevation": 1,
    "metabolic": 1,
    "acidosis": 1,
    "based": 1,
    "historical": 2,
    "observations": 1,
    "epilepsy": 1,
    "patients": 2,
    "taking": 4,
    "fda": 7,
    "requiring": 1,
    "company": 2,
    "perform": 1,
    "postapproval": 1,
    "cardiovascular": 2,
    "outcomes": 1,
    "trial": 1,
    "part": 1,
    "observation": 1,
    "cause": 3,
    "fetal": 1,
    "harm": 1,
    "data": 2,
    "registries": 1,
    "epidemiology": 1,
    "studies": 1,
    "indicate": 1,
    "fetus": 2,
    "exposed": 1,
    "first": 1,
    "trimester": 1,
    "risk": 3,
    "oral": 2,
    "clefts": 1,
    "cleft": 3,
    "lip": 1,
    "without": 1,
    "palate": 1,
    "patient": 2,
    "becomes": 1,
    "pregnant": 1,
    "treatment": 2,
    "discontinued": 1,
    "immediately": 1,
    "apprised": 1,
    "potential": 4,
    "hazard": 1,
    "females": 2,
    "reproductive": 2,
    "negative": 1,
    "test": 1,
    "starting": 1,
    "monthly": 1,
    "thereafter": 1,
    "therapy": 2,
    "effective": 1,
    "contraception": 1,
    "evaluation": 2,
    "mitigation": 2,
    "strategy": 2,
    "rems": 1,
    "ensure": 1,
    "benefits": 1,
    "outweigh": 1,
    "risks": 1,
    "contraindications": 1,
    "contraindicated": 1,
    "hyperthyroidism": 1,
    "within": 1,
    "14": 1,
    "days": 1,
    "monoamine": 1,
    "oxidase": 1,
    "inhibitors": 1,
    "hypersensitivity": 1,
    "idiosyncrasy": 1,
    "sympathomimetic": 1,
    "amines": 1,
    "increase": 1,
    "resting": 1,
    "history": 1,
    "developed": 1,
    "vivus": 6,
    "california": 1,
    "pharmaceutical": 1,
    "december": 1,
    "2009": 1,
    "inc": 2,
    "submitted": 1,
    "new": 1,
    "application": 1,
    "nda": 4,
    "march": 1,
    "2010": 2,
    "announced": 2,
    "accepted": 2,
    "decision": 1,
    "approve": 1,
    "current": 1,
    "form": 1,
    "issued": 1,
    "complete": 1,
    "response": 1,
    "letter": 1,
    "lack": 1,
    "including": 1,
    "elevated": 1,
    "major": 1,
    "birth": 2,
    "defects": 2,
    "january": 1,
    "2011": 3,
    "expressed": 1,
    "requested": 1,
    "assess": 1,
    "feasibility": 1,
    "analyzing": 1,
    "existing": 1,
    "healthcare": 1,
    "databases": 1,
    "determine": 1,
    "incidence": 1,
    "offspring": 1,
    "women": 1,
    "migraine": 1,
    "prophylaxis": 1,
    "100": 1,
    "mg": 1,
    "resubmitted": 1,
    "responses": 1,
    "issues": 1,
    "addressed": 1,
    "crl": 1,
    "november": 1,
    "september": 1,
    "became": 1,
    "available": 1,
    "market": 1,
    "european": 1,
    "union": 1,
    "references": 1
  },
  "title-length": 1,
  "content-length": 462,
  "curious_frequency": 1,
  "uplifting_frequency": 0,
  "entertaining_frequency": 1,
  "sad_frequency": 5,
  "general_frequency": 0
}